Navigation Links
S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Date:11/27/2007

SINGAPORE, Nov. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the expansion of its proprietary pipeline, with its third development candidate, SB1317. This is a novel orally-available small molecule compound targeted for the treatment of acute leukemias.

SB1317 is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. Flt3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia (AML) patients and are associated with a poor prognosis. In addition, over-expression of wild type Flt3 has been found in acute lymphoblastic leukemia (ALL) patients. Cyclin-dependent kinases or CDKs play important roles in cell cycle control. By inhibiting both Flt3 and CDK kinases, SB1317 is uniquely positioned as a "first-in-class" compound to treat relapsed and refractory acute leukemias. SB1317 has already entered preclinical development.

"The ability to maintain long-term control in AML and ALL remains one of the most significant unmet medical needs in the adult leukemia market. SB1317 has been designed with this in mind, and we believe it has the potential to become a first of its kind Flt3 inhibitor to specifically target this group of patients," said Dr. Jan-Anders Karlsson, CEO of S*BIO, "With its ideal profile for treating relapsed and refractory AML and ALL, SB1317 provides an opportunity for S*BIO to expand its portfolio of new targeted therapies for hematological disorders."

Approximately 300,000 new cases of leukemia are diagnosed worldwide each year, and there are about 36,000 new cases of acute leukemia in the seven major pharmaceutical markets*. Acute leukemia is characterized by rapid growth and accumulation of immature blood cells in the bone marrow. This results in fewer normal blood cells. Relapse rates following conventional leukemia treatments remain high and limited treatment options exist for patients who relapse after standard
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Rohm and Haas Expands in India
3. US Med-Equip Expands Corporate Support Center
4. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
5. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
6. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
7. Specialty Blades, Inc. Expands Management Team With New VP Engineering
8. CRH Medical expands Las Vegas operations
9. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
10. Bipartisan Bill Expands Health Care Access for Small Businesses
11. ABR-Affinity BioReagents Expands 100% Quality Guarantee

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Walking and cycling plus low-emission vehicles m..., , FRIDAY, Nov. 27 (HealthDay News) -- E...ad of using cars would offer much greater public h... vehicles, U.K. researchers have found. , The s... of alternative urban land transport scenarios for...
(Date:11/27/2009)... , Specialist manufacture...r products are saving millions of dollars by bring...ign process. Increasing numbers of pro-active medi... experts at the concept stage of their projects, e...xisting design processes or potentially outdated t...
(Date:11/26/2009)... , The copper sequestering drug tetrathiomolybdat...n the treatment of Wilson disease, a disease cause... cancers. That much is known. Very little, however...ar level. , A new study led by Northwestern Univ...clue: the three-dimensional structure of TM bound ...
(Date:11/26/2009)... , Research Triangle Dent...central North Carolina, today announced the expans...ified LUMINEER Dentist, Dr. Doug Macmillan. , ...arch Triangle Dental is pleased to announce that D...ist, recently completed an additional advanced tra...
(Date:11/25/2009)... ,, EMERYVILLE,Calif.,Nov.25/PRNewswire-Firs...odayannouncedthatthecompanywillhosttwoinvestoreven...er7,2009-9:00a.m.CT/10:00a.m.ET ,, Principali...gcarfilzomibinrelapsedand/orrefractorymultiplemyel...(ASH)AnnualMeetingandExpositioninNewOrleans,LA.The...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...pharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiop...hat production of its flagship drug, Cisatracurium...of 2009 compared to production in the first quarte...e first quarter of 2009, compared to 47,700 units ...
...es ,live, , , WASHINGTON, May 14 Starting Monday... connected by voice, video and data lines to speci...ferral center 130 miles away. A year after announc...t critical care to their patients, the first hospi...
...u best for this high-risk group, agency says , ...ealth officials said they,re seeing some complicat...es to spread across the country, and that this hig...t,s the seasonal influenza or pandemics of the pas...
...therapy led to better post-discharge function, stu...ews) -- Interrupting the sedation of critically il...age them in brief physical therapy may lead to bet...ase are often complications of the immobilization ...
...o the Stem for Life Foundation , , NEW YORK, May ...oneering the pre-disease collection, processing an... medical need, announced today it has signed an ag... supplement - AIO Premium Cellular Health. , , ...
...d Their Own as Downturn Took Hold , , WASHINGTON,...rofit hospitals and health care systems in the U.S...isers in charge of major gifts and planned giving ...her important findings come from the latest series...
Other Medicine News:Health News:Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 2008 2Health News:Maryland ICU Patients Connected to Remote Critical Care Staff, Improving Quality and Safety 2Health News:Maryland ICU Patients Connected to Remote Critical Care Staff, Improving Quality and Safety 3Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 2Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 3Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 4Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 5Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 6Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 7Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 8Health News:CDC: Flu Drugs Should Be 1st Choice for Pregnant Women With Swine Flu 9Health News:Early Exercise Boosts Outcomes for ICU Patients 2Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 2Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 3Health News:Hire More Fundraising Rain-Makers During Recession, New AHP Study Concludes 2
(Date:11/25/2009)...Nov.25/PRNewswire/--Reportlinker.comannouncesthata...,, IntranasalDrugDelivery-USMarketTrends&A...anasal-Drug-Delivery---US-Market-Trends--Analysis....nessinganexpansionoftherapeuticapplicationsfromthe...liveryofsystemictherapeuticdrugs.Thefutureofthetec...
(Date:11/24/2009)...,Md.,Nov.24/PRNewswire-Asia/--ChindexInternational...ntAmericanproviderofWestern,healthcareproductsands...dthattheCompanywillattendthe21stAnnualPiperJaffray...-2,2009,atthe,NewYorkPalaceHotel. , Managemen...,December1,2009,andholdone-on-onemeetingsthrougho...
(Date:11/24/2009)...Calif.,Nov.24/PRNewswire-FirstCall/--Vermillion,In...itsPlanofReorganizationandDisclosureStatementtoday...tfortheDistrictofDelaware.Ahearingtoconsiderapprov...ecember8,2009,withthehearingontheconfirmationofthe...ortheCompanytopayallclaimsinfull.ThePlanisexpected...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3New Survey Reveals High Expectations for Popular Aesthetic Injections 50856 1New Survey Reveals High Expectations for Popular Aesthetic Injections 50856 2New Survey Reveals High Expectations for Popular Aesthetic Injections 50856 3Robo bats with metal muscles may be next generation of remote control flyers 9130 1Robo bats with metal muscles may be next generation of remote control flyers 9130 2Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 1Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 2Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 3
... Drug,Administration (FDA) today issued the "<a ta...ives/criticalpath/reports/generic.html">Critical,P...ifying many,of the unanswered scientific questions...f commonly used drugs. , The report is part of FDA...o discern what challenges exist in moving a,promis...
...(ASX: GIA) today,announced that the US Food and Dr... Investigational New Drug application (IND),for th...nts with,Crohn,s Disease infected with Mycobacteri...y understands that its lead product, MyocondaR, is...this indication. There,are no anti-MAP therapies a...
Other Medicine Technology:New Critical Path Report Highlights Research Needed to Foster,Generic Drug Development 2FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4
...d a FAM-labeled probe targeting the glycoprotein D...a 532-labeled probe designed to detect the glycopr...nstrument that can detect FAM, Texas Red, and Alex...m. The Cepheid Analyte Specific Reagent* (ASR) pro...
...Acute Care Diagnostics, is a model of cost-effecti...etting. It's a random access analyzer, delivering ...ts from a whole blood sample in as little as 15 mi...e and rotor, load testpak(s) and press Start is e...
ThermoBrite
...ver one smooth pulse duration, rather than the mul...her technologies use. Palomar's Active Contact Coo...gh the StarLux handpiece, down to the sapphire tip...arLux full-color screen allows easy finger-touch o...
Medicine Products: